In my practice’s tertiary, referral dry eye center, we create a customized treatment plan selected from a number of therapeutic options and tailored to achieve the best outcomes for each individual patient—no matter the severity of their disease.

We use everything from device-based procedures (ie, TearCare System [SightSciences], Systane iLux [Alcon], and LipiFlow [Johnson & Johnson Vision]), in order to numerous prescription products (Eysuvis [loteprednol etabonate ophthalmic suspension 0.25%; Kala Pharmaceuticals], Xiidra [lifitegrast ophthalmic solution 5%; Alcon], Restasis [cyclosporine ophthalmic emulsion 0.05%; Allergan, an Abbvie Company], and Cequa [cyclosporine ophthalmic solution 0.09%; Sun Ophthalmics]), plus biologic products (ie, Regener-Eyes [Regener-Eyes LLC] plus Prokera [BioTissue]), and nutritional supplements (HydroEye; ScienceBased Health).

Cultivating positive word of mouth is a major component of growing any referral-based business. We are diligent with outreach to our OD network, providing them with continuing education programs and lectures. We also make use of our practice website and social media to share information about our own services, and we plan on restarting patient open houses and seminars that were suspended due to the particular pandemic.

Dry eye management is an integral part of the practice; we do not view it as separate because it feeds into everything else we do. All patients receive ocular surface treatments to ensure success with their cataract/refractive surgery or anything otherwise they are here for. As part of their surgical package, for example , all associated with our premium IOL individuals automatically receive a device-based dried out eye treatment. This is scheduled when they meet with our surgery coordinator.


To match patients along with the right therapies as well as ensure their adherence to treatment, all of us start with a comprehensive diagnostic evaluation that provides us with subjective and, more importantly, objective data. For the patient’s very subjective vantage point, we administer a questionnaire such as the OSDI or modified SPEED. We also ask patients about their symptoms and try to determine what will be most bothersome. It may be blurred or fluctuating vision or perhaps pain plus foreign body sensation.

The diagnostic workup, on the particular other hand, leverages objective tests in order to obtain detailed information regarding the patient’s underlying illness. The results of these tests give all of us a roadmap for therapy and give us a way to show sufferers what is happening on their ocular surface, along with visual evidence and numerical values. In our office, these include tear testing for osmolarity and inflammation as measured by MMP-9 (TearLab and InflammaDry; Quidel), dynamic meibomian gland imaging, and the corneal analyzer OPD-Scan III (Nidek) in order to evaluate the particular mires’ appearance.

Information from the objective tests helps us educate patients about their own condition. When they can see evidence of their particular dry eye, it motivates them to adhere to our treatment recommendations. If we all tell individuals their tear breakup time is 2 and they have 3+ superficial punctate keratitis at the slit lamp, that does not resonate. They will have the better grasp of the situation, however , whenever we show them distorted mires and significantly elevated osmolarity readings that will indicate the dehydrated state of the particular tear film. We can refer to images of the meibomian glands when we explain that they are not producing enough oil. All of us might use the HD Analyzer (Visiometrics) to show the goal scatter index or Cassini Technologies’ honeycomb pattern to show the particular tear movie surface disruption.


When patients understand what the objective tests are telling us about their condition, we can get their buy in with treatment. They will be more likely to opt for the recommended in-office interventions plus stick with their nutritional and pharmaceutical regimens. We all suggest HydroEye nutritional supplement as part associated with our patients’ care package because it is backed by scientific evidence through a clinical trial and data published in peer-review journals.

The particular omega fatty acid gamma linolenic acid (GLA), an anti-inflammatory omega-6 shown to play an important role in modulating the inflammatory response, is the particular product’s key ingredient. A unique omega, GLA is usually lacking in fish or even flax and is not really found in meaningful levels in our diet. GLA has been validated for improving dry vision symptoms in a variety of studies performed across a wide range of patient types. 1-7 HydroEye includes other omegas plus nutrient cofactors in a specific balance formulated in order to provide dry eye relief, an approach that offers more targeted and comprehensive support than fish oil omega-3s alone.

I explain that, just one therapy will not be enough; the layered therapy approach is definitely necessary to address the various underlying etiologies associated with their own ocular surface disease. We explain that will their condition, similar to the condition like high blood pressure, cannot be cured but it can be improved so that we can minimize its negative impact on their quality of life. We might do an in-office procedure on the spot, along with starting them on their prescription plus nutritional regimens, or we may do a good in office treatment at the next follow up. We describe for sufferers their individualized treatment strategy that we developed based on the goal measures. Typically we see patients back in 6 weeks to evaluate their particular progress; all of us let them know that is how long it will take in order to see improvement and we all emphasize the particular importance of their adherence. We must even be willing to “fire” a patient who will not commit to the treatment plan.


It may seem overwhelming to get started managing dry eye with therefore many diagnostics and treatment options available, but with proper planning it does not have to be. I recommend creating a process with a stream-lined dry eyes evaluation, starting small and simply with a few analysis. Along along with the slit-lamp exam, this could include assessing tear breakup time, performing corneal staining, and image resolution the meibomian glands. Get at least 1 device such as a corneal topographer to show patients objective signs of the dry ocular surface.

Next, develop the treatment plan and create a variety associated with dry eye packages for individuals from because simple as a good OTC artificial rip to the full bundle with 3- to 6-month supply of HydroEye/TearCare single treatment/prescription for immunomodulator. Invest in from least a single in-office restorative devices. Have a referral protocol for those patients you do not wish to treat, and consider selling products like HydroEye in the office for patients’ convenience and to generate income.


Just like they would have an evaluation for cataracts, refractive surgery, keratoconus, or presbyopia, patients should receive a dry attention evaluation. The evaluation can be associated with a process in terms of the accompanying diagnostic assessments, treatments, plus pricing with regard to the noncovered therapies. Be ready to clarify the dried out eye deals and their associated prices. Incorporating the particular appropriate diagnostics and remedies for dry eyes to ensure comprehensive care of these patients should be a process-driven endeavor. By creating customized packages that incorporate the range of analysis and treatment options available, practices can simplify dry eye management and improve patients’ outcomes.

Mitchell The. Jackson, MD

E: [email protected] com

Jackson is the founder plus CEO of Jacksoneye inside Lake Villa, Illinois. He is the consultant in order to Alcon, Johnson & Manley Vision, Sight Sciences, Tear Lab, Quidel, and ScienceBased Health.


1 . Barabino S, Rolando M, Camicione P, et al. Systemic linoleic and gamma-linolenic acid treatment in dry eyes syndrome with an inflammatory component. Cornea . 2003; 22(2): 97-101. doi: 10. 1097/00003226-200303000-00002.

two. Macrì A, Giuffrida H, Amico V, et ing. Effect of linoleic acid and gamma-linolenic acid on tear production, rip clearance plus on the particular ocular surface area after photorefractive keratectomy. Graefes Arch Clin Exp Ophthalmol . the year 2003; 241(7): 561-566. doi: ten. 1007/s00417-003-0685-x.

3. Aragona G, Bucolo C, Spinella R, et ‘s. Systemic Omega-6 essential fatty acid therapy and PGE1 tear content in Sjogren’s syndrome sufferers. Invest Ophthalmol Vis Sci . 2005; 46: 4474-4479. doi: 10. 1167/iovs. 04-1394.

4. Kokke KH, Morris JA, Lawrenson JG. Oral omega-6 essential fatty acid treatment in contact lens associated dry eyesight. Cont Lens Anterior Eye . 2008; 31: 141-146. doi:   10. 1016/j. clae. 2007. 12. 001

5. Pinna A, Piccinini P, Carta F. Effect of oral linoleic and gamma-linolenic acidity on meibomian gland dysfunction. Cornea. 3 years ago; 26(3): 260-4. doi: ten. 1097/ICO. 0b013e318033d79b.

6. Brignole-Baudouin F, Baudouin C, Aragona P, et al. The multicentre, double-masked, randomized, controlled trial evaluating the effect of dental supplementation associated with omega-3 plus omega-6 greasy acids on a conjunctival inflammatory marker within dry eye patients. Acta Ophthalmol . 2011; 89(7): e591-7. doi: 10. 1111/j. 1755-3768. 2011. 02196. x.

7. Sheppard JD, Singh R, McClellan AJ, ainsi que al. Long-term supplementation with n-6 and n-3 PUFAs improves moderate-to-severe keratoconjunctivitis sicca: a randomized double-blind clinical trial. Cornea. 2013; 32: 1297-1304. doi: 10. 1097/ICO. 0b013e318299549c.

Leave a Reply

Your email address will not be published.